arrow_back Back Filing freshness 10-Q Q1 FY2026 SEC EDGAR

CYTOKINETICS INC

CYTK
$76.72 ▲ +0.77 (+1.01%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
77 Visible periods
30 Metrics
Peer-ranked Benchmarks
Price Chart
77
Health
Good
Bullish
auto_awesome

Analytical Summary

CYTOKINETICS INC shows strong fundamentals with top-quartile Return on Common Equity (%) and Debt to Equity. The company's metrics support a bullish outlook for growth-oriented investors.

Market Cap $9.5M
Dividend Yield
Revenue Growth 1125.8%
Op. Margin None
ROIC 25.0%
FCF / Share None
Trailing P/E
Price / Book
FCF Yield
Debt / Equity -0.30
info Valuation on last close. End-of-day price, Aug 7, 2026.

77-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$19.36M
↑ +1125.8%
Net Income Profit after all expenses
$-206.03M
↓ -27.7%
Operating Margin Operating profit as % of sales
-167.0%
↓ -1266.4%
Long-Term Debt Long-term obligations
$247.21M
— +0.3%
trending_up

Bullish Indicators

  • Debt to EquityDebt to Equity is in the top quartile (lower is better)
  • Return on Common Equity (%)Return on Common Equity (%) is in the top quartile
warning

Bearish Risks

  • No bearish risks detected.

Health Breakdown

Returns
99
Financial Health
64
Cash Quality
48

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 28 years · 77 quarters